Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Google Secures Pentagon AI Deal for Classified Projects 
SAN DIEGO, April 20, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will present at the 5th Annual Cell & Gene Therapy Investor Day in Boston on Thursday, April 27, 2017 at 9:25 a.m. ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]
